《Nature,10月27日,Comparative ACE2 variation and primate COVID-19 risk》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-11-17
  • Comparative ACE2 variation and primate COVID-19 risk
    Amanda D. Melin, Mareike C. Janiak, Frank Marrone III, Paramjit S. Arora & James P. Higham
    Communications Biology volume 3, Article number: 641 (2020)

    Abstract
    The emergence of SARS-CoV-2 has caused over a million human deaths and massive global disruption. The viral infection may also represent a threat to our closest living relatives, nonhuman primates. The contact surface of the host cell receptor, ACE2, displays amino acid residues that are critical for virus recognition, and variations at these critical residues modulate infection susceptibility. Infection studies have shown that some primate species develop COVID-19-like symptoms; however, the susceptibility of most primates is unknown. Here, we show that all apes and African and Asian monkeys (catarrhines), exhibit the same set of twelve key amino acid residues as human ACE2. Monkeys in the Americas, and some tarsiers, lemurs and lorisoids, differ at critical contact residues, and protein modeling predicts that these differences should greatly reduce SARS-CoV-2 binding affinity. Other lemurs are predicted to be closer to catarrhines in their susceptibility. Our study suggests that apes and African and Asian monkeys, and some lemurs, are likely to be highly susceptible to SARS-CoV-2. Urgent actions have been undertaken to limit the exposure of great apes to humans, and similar efforts may be necessary for many other primate species.

  • 原文来源:https://www.nature.com/articles/s42003-020-01370-w
相关报告
  • 《Nature,3月30日,Interaction between RAAS inhibitors and ACE2 in the context of COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-31
    • Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 Jean-Jacques Mourad & Bernard I. Levy Nature Reviews Cardiology (2020) In the Comment article by Zheng and colleagues (COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-020-0360-5 (2020)), the crucial role of angiotensin-converting enzyme 2 (ACE2) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), was highlighted. ACE2 is a membrane-bound aminopeptidase that cleaves angiotensin I and angiotensin II into the angiotensin-(1–9) and angiotensin-(1–7) peptides. Several studies support the existence of a cardiovascular-protective ACE2–angiotensin-(1–7)–Mas receptor axis.
  • 《Nature,4月27日,Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-28
    • Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19 Hisashi Kai & Mamiko Kai Hypertension Research (2020) Abstract The rapid spread of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to an ongoing pandemic of coronavirus disease 2019 (COVID-19). Recently, angiotensin-converting enzyme 2 (ACE2) has been shown to be a functional receptor for SARS-CoV-2 to enter host target cells. Given that angiotensin receptor blockers (ARBs) and an ACE inhibitor (ACEI) upregulated ACE2 expression in animal studies, the concern might arise regarding whether ARBs and ACEIs would increase the morbidity and mortality of COVID-19. On the other hand, animal data suggested a potential protective effect of ARBs against COVID-19 pneumonia because an ARB prevented the aggravation of acute lung injury in mice infected with SARS-CoV, which is closely related to SARS-CoV-2.